CAMBRIDGE, Mass., Sept. 20, 2017 -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the Ladenburg Thalmann 2017 Healthcare Conference at the Sofitel Hotel in New York City on Tuesday, Sept. 26, 2017, at 3:00 p.m. EDT.
The presentation will be webcast live at http://wsw.com/webcast/ladenburg3/vcel and may be accessed from the news and events section of the Vericel website.
About Vericel Corporation
Vericel develops, manufactures, and markets expanded autologous cell therapies for the treatment of patients with serious diseases and conditions. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. Vericel is developing ixmyelocel-T, an autologous multicellular therapy intended to treat advanced heart failure due to ischemic dilated cardiomyopathy. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2017 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922


FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Washington Post Publisher Will Lewis Steps Down After Layoffs
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 



